
Agenus (AGEN) Stock Forecast & Price Target
Agenus (AGEN) Analyst Ratings
Bulls say
Agenus Inc possesses a strong clinical pipeline focused on cancer therapies, which is bolstered by proprietary products such as botensilimab (AGEN1811) and balstilimab, targeting mechanisms for immune activation. The potential for additional revenue generation through compassionate use programs for these therapies is promising, as it not only provides funding but also aids in gathering real-world clinical data to reinforce their efficacy. Furthermore, encouraging preliminary regulatory sentiment regarding bot/bal in the context of metastatic microsatellite-stable colorectal cancer (MSS-CRC) and efficacy seen in triple-negative breast cancer (TNBC) and ER+ breast cancer enhances the company's value proposition and growth prospects.
Bears say
Agenus Inc faces significant risks that could adversely impact its stock performance, primarily stemming from potential safety signals in its clinical programs and the possibility of lower-than-expected efficacy in its studies. The company may also encounter heightened commercial competition in the oncology space, alongside regulatory concerns that could affect the progression of its therapies. Additionally, financing requirements and challenges regarding intellectual property protection further contribute to a negative outlook for the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.
Agenus (AGEN) Analyst Forecast & Price Prediction
Start investing in Agenus (AGEN)
Order type
Buy in
Order amount
Est. shares
0 shares